¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06
±³À°ÀÏÀÚ : 2019-04-06
±³À°Àå¼Ò : ¼¼ºê¶õ½ºº´¿ø Á¾ÇÕ°ü 3Ãþ 337È£  
±³À°ÁÖÁ¦ : ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѹé¹ÝÁõÇÐȸ  
´ã´çÀÚ : ¿À»óÈ£
¿¬¶ôó : 02-2228-2080  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í ÇöÀåµî·Ï¸¸ °¡´É: ÇǺΰúÀü¹®ÀÇ 2¸¸¿ø, ÇǺΰúÀü°øÀÇ 1¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-06 337È£ 13:10~13:30 Interplay between oxidative stress and immune system  ¿À»óÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 13:30~13:50 A symphony of various kinds of immune cells responsible for vitiligo  ÀÌ»óÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 13:50~14:10 Melanocyte stem cells and paracrine factors for melanocyte regeneration in vitiligo  °­Èñ¿µ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:10~14:30 Pratical tips for the treatment of segmental vitiligo  À̵¿À±(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:30~14:50 Protocols of phototherapy in vitiligo treatment  ½ÅÁ¤Çö(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:50~15:10 The bottomline of surgical treatments of vitiligo  ¹ÚÁöÈÆ(¿ìÅÂÇÏÇѽ°æÇǺΰú) 
È޽Ġ04-06 337È£ 15:10~15:40 coffee break  () 
±³À°½Ã°£ 04-06 337È£ 15:40~16:10 FoxP3 regulatory T cells in immune-mediated tissue injury  ÃÖÀ±¼®(Ãæ³²ÀÇ´ë Ç÷¾×³»°ú) 
±³À°½Ã°£ 04-06 337È£ 16:10~16:30 Introduction of recent clinical trials and upcoming targeted medical therapy  ¹èÁ¤¹Î(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 16:30~16:50 Immune checkpoint blockers and vitiligo  ÃÖÁ¾¿ø(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 16:50~17:10 Comorbidities of vitiligo and laboratory tests for evaluation of comorbidities  ÀÌÈñÁ¤(Â÷ÀÇ°ú´ë) 
±³À°½Ã°£ 04-06 337È£ 17:10~18:00 Development of vitiligo after immunotherapy for breast cancer  ±èÁ¦¹Î(¿¬¼¼ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ»êºÎÀΰúÀÇ»çȸ Á¦41Â÷ Ãá°èÇмú´ëȸ : 2019-04-07
´ÙÀ½±Û ±¤ÁÖÀü³²°³¿ø³»°úÀÇ»çȸ Ãá°èÇмú´ëȸ : 2019-04-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
435 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ The 17th Postgraduate Course of Diabetes : 2018-09-15 0 845 2018-08-15
434 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-15 0 878 2018-08-15
433 Á¦ÁÖ ´ëÇÑÄ¡·áÃÊÀ½ÆÄÇÐȸ Á¦4ȸ Á¤±âÇмú´ëȸ : 2018-09-14 0 962 2018-08-15
432 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 3ÀÏÂ÷ : 2018-09-14 0 2,506 2018-08-15
431 °æ³² ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ ¿µ³²ÁöºÎ 2018³â 9¿ù Áý´ãȸ : 2018-09-14 0 969 2018-08-15
430 °æ±â ±¹¸³¾Ï¼¾ÅÍ 2018³â 3Â÷ ÀÇ»ý¸í°úÇÐÆ÷·³ : 2018-09-14 0 765 2018-08-15
429 ¼­¿ï °¡Å縯´ëÇб³¼­¿ï¼º¸ðº´¿ø °³¿øÀÇ ¿¬¼ö±³À° : 2018-09-14 0 627 2018-08-15
428 ÃæºÏ Á¦11Â÷ ´ëÇÑÁßÀçÇ÷°ü¿Ü°úÇÐȸ ½ÉÆ÷Áö¾ö : 2018-09-14 0 1,482 2018-08-15
427 ¼­¿ï Á¦74Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ Çмú´ëȸ(KCR 2018) 2ÀÏÂ÷ : 2018-09-13 0 1,545 2018-08-15
426 ¼­¿ï ÀÎÁ¦´ëÇб³»ó°è¹éº´¿ø À̺ñÀÎÈÄ°ú Áý´ãȸ : 2018-09-11 0 508 2018-08-15
425 °æ±â ÇѾç´ëÇб³±¸¸®º´¿ø °©»ó¼± Á¾¾çÀÇ Áø´Ü°ú Ä¡·á: Ãֽŵ¿Çâ : 2018-09-11 0 453 2018-08-15
424 ºÎ»ê Á¦493Â÷ ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2018-09-10 0 508 2018-08-15
423 ¼­¿ï °¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ 12ȸ °¡Å縯¼ºÇü½ÉÆ÷Áö¾ö : 2018-09-09 0 791 2018-08-15
422 ¼­¿ï Á߾Ӵ뺴¿ø È£Èí±â¾Ë·¹¸£±â³»°ú ¿¬¼ö°­Á : 2018-09-09 1 793 2018-08-15
421 ¼­¿ï ´ëÇѼºÇü¿Ü°úÇÐȸ Ç׳ëÈ­¼ºÇü¿¬±¸È¸ Á¦4ȸ ½ÉÆ÷Áö¾ö : 2018-09-09 0 805 2018-08-15
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷